Psychotic behaviour – European Clinical Trials Information Network

Study on Reducing Antipsychotic Dose vs. Maintenance Treatment for Patients with Schizophrenia Using Haloperidol Decanoate, Risperidone, and Amisulpride

Wed, 29 Apr 2026 15:04:57 +0000

This clinical trial is focused on studying the effects of different treatment strategies for patients diagnosed with schizophrenia spectrum disorder. This includes conditions such as schizophrenia, schizophreniform disorder, schizoaffective disorder, or brief psychotic episodes. The study will compare two approaches: reducing the dose of antipsychotic medications or maintaining the current treatment. The medications involved in this study include haloperidol decanoate, risperidone, amisulpride (also known as APD421), loxapine succinate, flupentixol decanoate, pregabalin, chlorpromazine hydrochloride (also known as aminazine), levomepromazine hydrochloride, aripiprazole, pipotiazine palmitate, and fluoxetine hydrochloride.

The purpose of the study is to determine if there is a difference in the effectiveness of these two treatment strategies based on the type of psychotic symptoms a patient experiences. The study will last for up to 24 months, during which patients will be monitored to see how well they function in their daily lives. This will be assessed using a scale called the Personal and Social Performance Scale (PSP). Patients will have regular check-ins with their healthcare providers and a specialized evaluation team to track their progress.

Throughout the study, various aspects of the patients’ health will be monitored, including any side effects from the medications, their overall well-being, and their quality of life. The study aims to provide insights into how personalized treatment plans can improve outcomes for individuals with schizophrenia spectrum disorders. The ultimate goal is to find the most effective way to manage these conditions while minimizing side effects and improving patients’ quality of life.

Study on Continuing or Reducing Antipsychotic Medication (Haloperidol, Clozapine, Tiapride) for Patients After First Episode of Psychosis

Wed, 29 Apr 2026 15:01:58 +0000

The HAMLETT study focuses on patients who have experienced a first episode of psychosis and are currently in remission, meaning their symptoms have improved or disappeared. The study examines the effects of continuing versus reducing or stopping the use of antipsychotic medication after this initial recovery. The medications being studied include Haloperidol, Clozapine, Tiapride, Sertindole, Paliperidone, Olanzapine, Sulpiride, Aripiprazole, Lurasidone, Risperidone, Amisulpride, Chlorpromazine, Pimozide, and Quetiapine. The purpose of the study is to understand how these different approaches affect personal and social functioning over both the short term (1-2 years) and long term (3-4 years).

Participants in the study will be randomly assigned to either continue their current antipsychotic medication or to gradually reduce or stop it. The study will monitor various aspects of their health and well-being, including any side effects from the medication, overall quality of life, and any changes in their physical and mental health. The study will also look at how these changes affect their ability to function in daily life, including their social interactions and personal well-being.

The study will take place over several years, with regular check-ins to assess the participants’ progress. The primary focus is on long-term social recovery, which is considered important by both patients and their families. Additional factors being monitored include the severity of any remaining symptoms, physical health indicators like body mass index, and any instances of aggression or self-harm. The study aims to provide valuable insights into the best treatment strategies for individuals recovering from a first episode of psychosis.

Study on Cannabidiol and Aripiprazole for Treating Substance-Induced Psychosis in Young Patients

Wed, 29 Apr 2026 14:59:21 +0000

This clinical trial is focused on studying the effects of cannabidiol (CBD) as an additional treatment for young patients experiencing Substance-Induced Psychosis, a condition where drug use leads to symptoms of psychosis, such as hallucinations or delusions. The study will also involve patients with Cannabis Use Disorder, which is characterized by a problematic pattern of cannabis use leading to significant impairment or distress. The trial will compare the effects of CBD with a placebo, alongside the use of aripiprazole, an antipsychotic medication. Aripiprazole will be administered in different forms, including oral solutions and tablets, as well as long-acting injections.

The purpose of the study is to determine if CBD can help reduce the symptoms of cannabis use relapse in patients who are already receiving antipsychotic treatment. Participants will be randomly assigned to receive either CBD or a placebo, in addition to their regular antipsychotic medication. The study will last for six months, during which participants will be monitored for changes in their symptoms and overall health. Regular assessments will be conducted to track the progress of each participant, and the results will be analyzed to see if there is a significant difference between the group receiving CBD and the group receiving the placebo.

Throughout the study, participants will continue their treatment with aripiprazole, which may be switched from oral to long-acting injection form. The trial aims to provide insights into whether CBD can be a beneficial addition to existing treatments for young individuals dealing with substance-induced psychosis and cannabis use disorder. The findings could potentially lead to improved treatment strategies for managing these conditions.